Northwire Canada EditionSunday, August 2, 2026
Sign inSubscribe
Northwire
⌕
S 0.140 +0.0% BNKR 4.40 −2.2% QRO 0.045 +0.0% VCT 0.075 +36.4% PPP 1.15 +0.9% LMG 0.390 +0.0% GRDM 0.140 +0.0% ABRA 13.58 −4.1% WHY 0.295 +1.7% HHH 3.94 −0.2% COS 0.060 +0.0% NOB 0.065 −23.5% MEK 0.055 +0.0% TGOL 0.105 −4.5% FCI 0.400 −7.0% SGQ 0.350 +0.0% S 0.140 +0.0% BNKR 4.40 −2.2% QRO 0.045 +0.0% VCT 0.075 +36.4% PPP 1.15 +0.9% LMG 0.390 +0.0% GRDM 0.140 +0.0% ABRA 13.58 −4.1% WHY 0.295 +1.7% HHH 3.94 −0.2% COS 0.060 +0.0% NOB 0.065 −23.5% MEK 0.055 +0.0% TGOL 0.105 −4.5% FCI 0.400 −7.0% SGQ 0.350 +0.0%
Financings

StageZero Announces Partial Revocation of Failure to File Cease Trade Order and Proposed Financing

By The Northwire Desk — AI Analysis Jan 20, 2026 · 19:30 SZLS · None STAGEZERO LIFE SCIENCES LTD. J
SZLS · Price

Executive Summary

  • The Ontario Securities Commission issued a Partial Revocation Order allowing StageZero Life Sciences to conduct a private placement of up to $2.5 million in secured convertible debentures.
  • The offering consists of $1,000 principal amount debentures bearing 8‑12% interest per annum; conversion into common shares is prohibited until a full revocation order is obtained.
  • Proceeds will be used to pay outstanding fees, prepare audited financial statements, fund the application for a full revocation of the cease‑trade order, and provide general working capital.

Key Details

  • Partial Revocation Order (Jan 19 2026): Allows private placement despite existing failure‑to‑file cease‑trade order (FFCTO) issued Apr 8 2024.
  • Private Placement Size: Up to $2,500,000 total principal.
  • Instrument: Secured convertible debentures, $1,000 each, interest 8‑12% per annum.
  • Conversion Restriction: Debentures cannot be converted into common shares until a full revocation order is obtained.
  • Use of Proceeds:
  • Pay outstanding regulatory and professional fees.
  • Prepare audited annual financial statements.
  • Cover costs associated with applying for a full revocation of the FFCTO.
  • Remainder allocated to general working capital.
  • Offering Mechanics: Conducted on a prospectus‑exempt basis under accredited investor exemptions (NI 45‑106, Section 73.3). Subscribers located in Ontario, British Columbia, and Alberta.
  • Regulatory Approvals: Financing subject to approval by the NEX; application for such approval is underway.
  • Investor Acknowledgement: Prior to closing, each investor must receive copies of the FFCTO and Partial Revocation Order and sign an acknowledgement that all securities remain subject to the FFCTO until full revocation.
  • No Guarantees: Company states there is no assurance the financing will be completed on the outlined terms or that proceeds will be sufficient for intended purposes.

Notable Quotes

(None provided in the release)

Read the original news release →